Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12653434 | 0.92 | L3MBTL1 (0.43) | L3MBTL1SLC6A4SLC6A3SLC6A2ALDH1A1 | |
| SCHEMBL1805474 | 0.86 | KAT2B (0.36) | SLC6A4SLC6A3SLC6A2ALDH1A1TSHR | |
| SCHEMBL14944333 | 0.83 | SLC6A4 (0.40) | SLC6A4SLC6A3SLC6A2ALDH1A1TSHR | |
| SCHEMBL437413 | 0.82 | EPHX2 (0.43) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14944332 | 0.77 | POLB (0.52) | SLC6A4SLC6A3ALDH1A1MAPTMEN1 | |
| SCHEMBL14944331 | 0.76 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2ALDH1A1TSHR | |
| SCHEMBL12653435 | 0.75 | PSEN1 (0.38) | SLC6A4SLC6A3SLC6A2TSHRCASP1 | |
| SCHEMBL12000527 | 0.75 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14944335 | 0.74 | ALDH1A1 (0.44) | SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL21131084 | 0.71 | SLC6A4 (0.49) | L3MBTL1SLC6A4SLC6A3SLC6A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592071-B1 | Tricyclic heterocyclic compounds | BRISTOL MYERS SQUIBB CO (US) | 2019-09-18 | — | — | EP | disclosed |
| US-9216972-B2 | Tricyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2592071-A1 | Tricyclic heterocyclic compounds | Bristol-Myers Squibb Company (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214767-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, TBXA2R | L3MBTL1 4429/4885SLC6A4 2800/4885SLC6A3 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.